Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Michael C. Milone · UNIVERSITY OF PENNSYLVANIA · 2024 · $565,591 — PROJECT SUMMARY / ABSTRACT (PROJECT 3) Multiple myeloma (MM) is a hematologic malignancy of bone marrow plasma cells. Even though MM is almost universally fatal, modern therapy has markedly improved survival. Among the most promising new MM therapies are CAR T cells targeting B cell maturation antig…
FRANCOIS VILLINGER · UNIVERSITY OF LOUISIANA AT LAFAYETTE · 2024 · $317,451 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
MARGIE L. CLAPPER · RESEARCH INST OF FOX CHASE CAN CTR · 2024 · $515,612 — Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While…
Jesse Hong-Sae Erasmus · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $2,091,310 — Abstract RNA vaccines have dramatically altered the landscape of vaccine development, affording an unparalleled ability to rapidly counteract emerging infectious diseases, as evidenced by the swift generation of effective RNA vaccines in response to the COVID-19 pandemic. However, despite these majo…
Karen S. Anderson · YALE UNIVERSITY · 2024 · $432,279 — SUMMARY Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC. The incidence of HPV+ HNSCC has dramatically increased over the last 2 decades and in 2012 surpassed uterine cervical cancer as the most common HPV-related malignancy in t…
Neil King · UNIVERSITY OF WASHINGTON · 2024 · $5,122,197 — PROJECT SUMMARY – PROJECT 3: ANTIGEN DESIGN Project 3 focuses on developing generalizable approaches to the modeling, design, and evaluation of native-like antigens for arenaviruses, phenuiviruses, and paramyxoviruses. Powerful machine-learning (ML) methods enable stabilization of antigens in desire…
JOHN P COOKE · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $333,348 — PROJECT SUMMARY RNA vaccines have quicker development timelines and are simpler to manufacture than traditional vaccines. Combining this strength of RNA technology with protein engineering, they hold the potential to generate highly efficacious vaccines rapidly that can target and harness the immune…
Scott F Michael · COLLEGE AT OSWEGO · 2023 · $158,723 — PROJECT SUMMERY Most currently available vaccines, especially live and mRNA-based COVID-19 vaccines, are temperature sensi- tive and require stringent cold-chain maintenance, entailing their storage and distribution at recommended tem- peratures from production to administration. This necessity impo…
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2023 · $1,357,000 — Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S…
Adolfo Garcia-Sastre · JACKSON LABORATORY · 2023 · $2,195,905 — PROJECT SUMMARY The WHO estimates that annual epidemics of influenza result in 3-5 million cases of severe illness and 300,000- 500,000 deaths. 90% of influenza-related deaths occur in older adults despite widespread vaccination programs with vaccines tailored for this high-risk group. The estimated…
Jianrong Li · OHIO STATE UNIVERSITY · 2023 · $468,678 — Abstract This application is to renew a grant to study RNA methylation in pneumoviruses. Pneumoviridae is a new virus family, created in 2016 by elevating the paramyxoviral subfamily Pneumovirinae to family status. The Pneumoviridae family includes two medically important pathogens, human respirator…
Johannes Morstein · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $163,080 — Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to treating cancer, including cancer immunotherapy, cancer nanotherapy (e.g. liposomal doxorubicin or mRNA vaccines), or new types of biologics and small molecules. I prop…
BALI PULENDRAN · STANFORD UNIVERSITY · 2023 · $2,168,222 — ABSTRACT – Overall Component In the current proposal we will use a systems vaccinology approach to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). Th…
Christopher S Anderson · UNIVERSITY OF ROCHESTER · 2023 · $101,672 — Respiratory Syncytial Virus (RSV) is the second leading cause of hospitalization in children worldwide and has been increasing appreciated as a cause of hospitalization and death in the elderly. Recent studies have shown that polyvalent vaccine formulations, mixture of antigens derived from distinct…
R. Brad Jones · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $211,875 — PROJECT SUMMARY/ABSTRACT Although modern therapies have dramatically improved the outlooks for people living with HIV they are unable to cure infection, leaving these individuals burdened by a lifelong commitment to antiretroviral (ARV) medication. For any given individual, maintaining lifelong adhe…
Guido Ferrari · DUKE UNIVERSITY · 2023 · $5,902,563 — ABSTRACT The ultimate goal of the proposed studies is to contribute to ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure has been elusive. In 2020, there was an estimated 37.6 million people living with HIV. D…
Yang Xu · LUNA LABS USA, LLC · 2023 · $296,815 — Project Summary Significant research has gone into the development of a safe and effective vaccine for HIV-1. Although many strategies have been attempted; none has been successfully established. Even a partially effective vaccine could decrease the number of people who are infected with HIV, furthe…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2023 · $627,134 — ABSTRACT Inherited retinal dystrophies (IRDs) are a heterogenous group of orphan diseases, inherited in an autosomal dominant, recessive or X-linked pattern in addition to mitochondrial transmission, all leading to the loss of functional vision and often progressing to blindness. As a group, IRDs ar…
FENGWEI BAI · UNIVERSITY OF SOUTHERN MISSISSIPPI · 2023 · $444,000 — Summary Zika virus (ZIKV) is a mosquito-transmitted flavivirus that has caused devastating congenital Zika syndromes (CZS), including microcephaly, congenital malformation, and fetal demise in human newborns in the 2015 - 2016 epidemics. In addition, ZIKV infection can cause Guillain-Barré syndrome …
Zhijian Jake Tu · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2023 · $774,520 — Abstract Sex is critical to the survival and evolution of sexually reproducing organisms including mosquitoes. A dominant male-determining factor (M factor) is the primary signal that controls sex-determination in mosquitoes. Nix, the M factor in the yellow fever mosquito Aedes aegypti, is the first…